Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment

Rivera, Daniel; Gomez, Juan Povedano; Bobadilla, J. Cacicedo Fernández de; Delgado, Domingo Acosta; Campo, Eleonor Rivin del; Praena-Fernández, Juan Manuel; Bernabé, Reyes; Gordillo, María Dolores Gordillo; Fernández, Mónica Alvarez; Guerra, José Luis López

doi:10.1007/s12094-019-02047-5

Cited by 16 publications

(8 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many studies have investigated risk factors for postoperative complications after major lung resection for NSCLC and CVC is an acknowledged risk factor for this operation ( 5 , 9 , 10 ). Ambrogi et al reported a significant difference in mortality and morbidity in patients with CVC undergoing minor or major lung resection for NSCLC (postoperative morbidity: 59% vs. 21% and 30-day mortality: 9% vs. 2.5%) ( 5 ).…”

Section: Discussionmentioning

confidence: 99%

Should cardiovascular comorbidities be a contraindication for pulmonary metastasectomy?

Grapatsas¹,

Hassan²,

Semmelmann³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

Background: Limited information is available about the impact of cardiovascular comorbidities (CVC) on the postoperative course of patients undergoing pulmonary metastasectomy. In this study, we aim to compare the postoperative morbidity, mortality, and the long-term survival of patients with and without CVC undergoing pulmonary metastasectomy (PM).Methods: A retrospective monocentric study was conducted including 760 patients who underwent PM in curative intention. Patients were divided into two groups depending on the presence of CVC. Results:The data from 164 patients with CVC (21.6%) and 596 patients without CVC (78.4%) were investigated. In both groups, zero in-hospital-mortality and limited 30-day mortality was detected.Postoperative complications occurred more often in patients with CVC (N=47, 28.7% vs. N=122, 20.5%, P=0.02). However, most of them were minor (N=37, 22.6% vs. N=93, 15.6%, P=0.03). The presence of multiple CVC (N=18 patients, 40% vs. N=28, 23.9%, P=0.04) and reduced left ventricular function (N=5, 62.5% vs. N=42, 27.1%, P=0.03) were identified as risk factors for postoperative morbidity. Patients with CVC showed reduced overall survival (5-year survival rate: 75.8% vs. 68%, P=0.03). In the multivariate analysis lobectomy [hazard ratio (HR) 0.3, 95% confidence interval (CI): 0.1-0.8, P=0.02] and general vascular comorbidities (HR 2.1, 95% CI: 1.1-3.9, P=0.01) were identified as independent negative prognostic factors.Conclusions: Resection of pulmonary metastases can be performed safely in selected patients with stable CVC. The presence of CVC in patients undergoing PM is associated with reduced overall survival compared to patients without CVC in the long term follow up. However, a prolonged 5-year survival rate of 68% could be achieved.

show abstract

Section: Discussionmentioning

confidence: 99%

Should cardiovascular comorbidities be a contraindication for pulmonary metastasectomy?

Grapatsas¹,

Hassan²,

Semmelmann³

et al. 2022

J Thorac Dis

View full text Add to dashboard Cite

show abstract

“…Cancer-associated inflammation not only contributes to tumor progression and metastasis, but also to the hypercoagulable state in patients with NSCLC [39][40][41] , so interfering with the interactions between cancer-associated inflammation and coagulation could represent a novel strategy for treating NSCLC and preventing venous thromboembolism. In the present study, two NSCLC cell lines, H1299 and A549 cells, were examined because they bear a p53 mutation and a KRAS mutation, respectively.…”

Section: Discussionmentioning

confidence: 99%

Golden berry 4β-hydroxywithanolide E prevents tumor necrosis factor α-induced procoagulant activity with enhanced cytotoxicity against human lung cancer cells

Hsieh

Tsai

Lin

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Inflammation in the tumor microenvironment is positively correlated with cancer progression and metastasis as well as the risk of thromboembolism in lung cancer patients. Here we show, in human non-small cell lung cancer (NSCLC) cell lines, the master inflammatory cytokine tumor necrosis factor (TNF-α) induced tissue factor expression and procoagulant activity, and these effects were potently inhibited by 4β-hydroxywithanolide E (4HW), a natural compound isolated from Physalis peruviana. Furthermore, combination of 4HW and TNF-α caused synergistic cytotoxicity against NSCLC cells by inducing caspase-dependent apoptosis. The underlying mechanism by which 4HW reverses the procoagulant effect of TNF-α but enhances its cytotoxic effect appears to be due to inhibition of NF-κB, which is a key switch for both inflammation-induced coagulation and cell survival. Our results suggest that 4HW may have a potential application for treating inflammation-derived cancer progression and cancer-associated hypercoagulable state.

show abstract

“…The study’s strengths lie in its adjustment for competing risks and large sample size ( n = 347,476), although it focuses on a specific subgroup of patients and its findings may therefore not be applicable to other cancer types [ 59 ]. In addition to not accounting for competing risks, other studies exploring CVD-related mortality in cancer survivors may also lack direct comparison with a cancer-free control group, limiting their ability to accurately capture the extent of the problem [ 60 , 61 ]. These studies do, however, allow examination of cardiovascular mortality trends and prognostic factors associated with CVD-related death in cancer survivors.…”

Section: Clinical Implications Of Cancer-related Cardiovascular Diseasementioning

confidence: 99%

Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology

et al. 2022

View full text Add to dashboard Cite

Purpose of Review Cardiovascular disease is long-term complication of both cancer and anti-cancer treatment and can have significant ramifications for health-related quality of life and mortality. This narrative review explores the current evidence linking cardiovascular disease and cancer, as well as exploring strategies for the prevention and management of cardiovascular disease, and outlines future opportunities in the field of cardio-oncology. Recent Findings Cancer confers risk for various cardiovascular diseases including heart failure, cardiomyopathy, arrhythmia, coronary heart disease, stroke, venous thromboembolism, and valvular heart disease. Cancer treatment, in particular agents such as platinum-based chemotherapy, anthracyclines, hormonal treatments, and thoracic radiotherapy, further increases risk. While cardiovascular disease can be identified early and effectively managed in cancer survivors, cardiovascular screening and management does not typically feature in routine long-term cancer care of adult cancer survivors. Summary Cancer and cancer treatment can accelerate the development of cardiovascular disease. Further research into screening and management strategies for cardiovascular disease, along with evidence-based guidelines, is required to ensure adult cancer survivors receive appropriate long-term care.

show abstract

Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment

Cited by 16 publications

References 29 publications

Should cardiovascular comorbidities be a contraindication for pulmonary metastasectomy?

Should cardiovascular comorbidities be a contraindication for pulmonary metastasectomy?

Golden berry 4β-hydroxywithanolide E prevents tumor necrosis factor α-induced procoagulant activity with enhanced cytotoxicity against human lung cancer cells

Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology

Contact Info

Product

Resources

About